Multimorbidity After Surgical Menopause Treated with Individualized Classical Homeopathy: A Case Report

Abstract

Classical homeopathy was shown to be beneficial in climacteric syndrome in many studies, but the clinical effect is unclear. To inspect if individualized classical homeopathy has a role in treating complaints after surgical menopause through real world case, we present a case of a 54-year-old Russian woman treated with individualized classical homeopathy for multimorbid conditions after surgical menopause examined for changes from homeopathic treatment. We assessed changes in climacteric symptoms, changes in comorbidities, and the general well-being of the patient. The woman had severe climacteric syndrome, pelvic inflammatory disease, dyslipidemia, obesity, hepatic steatosis, pancreatic lipomatosis, gall bladder disease, and mild subclinical hypothyroidism to begin with. She was treated with individualized classical homeopathy and followed up for 31 months. She was relieved of the vasomotor symptoms and psychological disturbances of climacteric syndrome, her weight reduced, the ultrasound scan showed absence of lipomatosis/gall bladder disease/hepatic steatosis. Blood tests showed reduction of thyroid stimulating hormone and a balance in the lipid status. Individualized classical homeopathy may have a role in the climacteric syndrome and comorbidities after surgical menopause. The efficacy of homeopathic therapy in climacteric problems must be scientifically investigated further.

Keywords: Surgical menopause; climacteric; comorbidities; dyslipidemia; homeopathy; hot flashes; individualized treatment; lipomatosis; obesity; subclinical hypothyroidism; vasomotor symptoms.

Figure 1.

Repertorisation of first consultation on MacRepertory.

Figure 2.

Repertorisation on 17/05/2017.

Figure 3.

Trend of lipid parameters and Thyroid Stimulating Hormone (TSH). Trend of lipid parameters and TSH. Total cholesterol: Reduced from 8.32 to 4.07 mmol/l (N: 3.10-5.16 mmol/l). High Density Lipids (HDL): Increased from 1.19 to 1.81 mmol/l (N: 1.0-2.07 mmol/l). Low Density Lipids (LDL): Reduced from 5.12 to 2.94 mmol/l (N: 1.71-3.40 mmol/l). Very Low Density Lipids (VLDL): Reduced from1.87 to 0.82 mmol/l (N: 0.26-1.04 mmol/l). Triglycerides: Reduced from 2.04 to 1.24 mmol/l (N: 0.45-1.60 mmol/l). Atherogenicity index: Reduced from 5.9 to 1.2 (N: 1.5-3). TSH: Reduced from 5.7 to 1.43 µIU/ml (N: 0.4–4 µIU/ml).